BioScrip Inc (NASDAQ:BIOS) shares fell 6.4% during trading on Tuesday . The stock traded as low as $3.21 and last traded at $3.22, 1,320,144 shares traded hands during trading. An increase of 19% from the average session volume of 1,111,232 shares. The stock had previously closed at $3.44.

A number of equities research analysts have weighed in on the company. BidaskClub raised BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 23rd. Canaccord Genuity raised their price target on BioScrip from $3.50 to $4.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. ValuEngine downgraded BioScrip from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Finally, Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $4.70.

The company has a market capitalization of $448.26 million, a PE ratio of -6.57 and a beta of 0.52. The company’s fifty day moving average is $3.11 and its 200-day moving average is $2.52.

BioScrip (NASDAQ:BIOS) last posted its earnings results on Tuesday, July 30th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04). The business had revenue of $191.52 million during the quarter, compared to the consensus estimate of $185.73 million. As a group, analysts predict that BioScrip Inc will post -0.18 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can bought a new stake in BioScrip during the second quarter valued at about $27,000. Jane Street Group LLC bought a new position in shares of BioScrip during the 2nd quarter worth approximately $30,000. SG Americas Securities LLC purchased a new stake in BioScrip during the first quarter valued at approximately $49,000. BNP Paribas Arbitrage SA lifted its position in BioScrip by 205.2% during the first quarter. BNP Paribas Arbitrage SA now owns 26,338 shares of the company’s stock valued at $53,000 after acquiring an additional 17,709 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in BioScrip by 11.2% in the second quarter. JPMorgan Chase & Co. now owns 36,469 shares of the company’s stock valued at $89,000 after acquiring an additional 3,683 shares in the last quarter. Hedge funds and other institutional investors own 77.52% of the company’s stock.

BioScrip Company Profile (NASDAQ:BIOS)

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Read More: Why is cost of goods sold important?

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.